XBiotech, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. Its lead product is MABp1, which is also known as Xilonix, a novel anti-cancer agent, which has completed Phase III clinical trial in Europe for the treatment of advanced colorectal cancer. MABp1 targets and neutralizes interleukin-1 alpha. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
XBiotech Plunges on Results of Colorectal Cancer Drug Trial XBiotech Inc. plunged a record 50 percent after a late-stage study of its lead drug, using an unconventional method to evaluate its cancer-fighting abilities, raised questions about any potential benefit for patients. Rather than the traditional approach of tracking tumor growth, the study reported on symptoms associated with disease progression, such as pain, fatigue, appetite and muscle loss, according to a company statement distributed Saturday. The study authors didn’t compare survival in patients given the drug -- Xilonix for colorectal cancer -- or placebo, a standard method of assessing effectiveness, because everyone in the trial was offered the drug after eight weeks, XBiotech said.
It took a huge dive today ! I am wondering to buy some since they still have some drugs under development. Any insights?
